Nuvilex: A Biotech Methodically Pursuing Cannabis Treatments for Cancer
May 13 2014 - 9:00AM
Marketwired
Nuvilex: A Biotech Methodically Pursuing Cannabis Treatments for
Cancer
NEW YORK, NY--(Marketwired - May 13, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) announced last week that it signed an agreement with
the University of Northern Colorado to perform initial studies in
the development of cancer treatments that combine the proprietary
live-cell encapsulation technology Cell-in-a-Box® with constituents
of cannabis known as cannabinoids. It was another quiet
announcement that seemed to fly under the radar, and maybe
purposely so, as Nuvilex is a biotechnology firm that wants to stay
just that, but at the same time, the company wants to use all
available tools to potentially improve its own cancer treatments
and, in turn, potentially save lives. And that means medical
marijuana needs to be an option given it has proven it has
medicinal properties.
So, in what has been Nuvilex's modus operandi over the last year
or so, the company has sought out cannabis industry professionals
in an attempt to position itself as a leader in medical
marijuana. Unlike many companies that reside permanently in
the cannabis space, putting out news daily with no substance and
seemingly no end in sight to the claims, Nuvilex has methodically
put together a world class Scientific Advisory Board (SAB) at its
wholly owned subsidiary Medical Marijuana Sciences.
Much like Nuvilex did when it assembled a who's who team of
world renowned oncologists to advance its pancreatic cancer
treatment, the company has put the same due diligence into naming a
Board of industry leaders to further its work toward developing
treatments that include cannabinoids.
Nuvilex may be a small biotechnology firm, but since turning its
focus strictly to operating as a biotech, it has made one big move
after another and seems to have a knack for finding the best of the
best to represent its research.
Last week's news stated that one of the members of its SAB,
Richard Hyslop, Ph.D., Professor of Chemistry and Biochemistry at
the University of Northern Colorado, will lead the efforts to
establish a solid foundation for future preclinical studies and
clinical trials that will be needed to develop treatments for
serious and deadly diseases such as brain and pancreatic
cancers.
Nuvilex's CEO Kenneth Waggoner said, "The goal is to develop a
Cell-in-a-Box®/cannabinoid combination that has anticancer effects
coupled with low toxicity similar in concept to Nuvilex's
pancreatic cancer treatment currently being prepared for Phase 2b
clinical trials that uses the Cell-in-a-Box® technology with low
doses of the chemotherapeutic drug ifosfamide."
Nuvilex is a biotech, but its execs are also wise enough to keep
all options open when it comes to improving its cancer treatments,
so using marijuana is always on the table. And, if actually
using the drug can further the company's treatments, then they'll
gladly be a leader in the industry.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a
platform for corporate stories to unfold in the media with Reports,
Interviews and Articles. SMMG is compensated for Nuvilex content by
a third party who reserves the right to buy, sell or remain neutral
on securities after the publication of this article. SMMG has
received total compensation of $84,595 for content related to
Nuvilex. Additionally, a principal at SMMG currently owns 200,000
total shares of Nuvilex issued by the company through a consulting
agreement which has since ended for work unrelated to content
development. The shares have been held for the requisite period
under Rule 144 as of April 30, 2013, and are eligible to be sold
immediately without further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact